Consorci Sanitari de Terrassa
Terrassa, Catalonia, 08227, Spain
Location status: Recruiting
Location contact
Joan Lozano, MD
CONTACT
Joan Lozano, MD
CONTACT
NCT Number: NCT03853733
Many patients with rectal cancer were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this prospective study is to describe the preliminary results of our protocol of hypofractionated palliative radiotherapy in patients with non-operable rectal cancer.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Terrassa, Catalonia, 08227, Spain
Location status: Recruiting
Joan Lozano, MD
CONTACT
Joan Lozano, MD
CONTACT
Many patients with rectal cancer were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this prospective study is to describe the preliminary results of our protocol of hypofractionated palliative radiotherapy in patients with non-operable rectal cancer.
Patients with rectal cancer who were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases at the time of diagnosis were considered eligible.
Patients were immobilized in the prone position with a belly-board in order to reduce small bowel irradiation. To limit organ motion patient were instructed to empty the bladder and drink 500cm3 of water 45-60 minutes before CT simulation and before every treatment fraction.
A conformal three-dimensional radiotherapy technique was planned to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
Symptomatic response after the end of treatment has been measured for bleeding and pain and acute toxicity were reported according to CTCAEv4.0 scale.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
Time frame: two months afer the end of radiotherapy
number of patients with bleeding ( worst, no change, better or without)
Time frame: two months afer the end of radiotherapy
number of patients with pain ( worst, no change, better or without)
Time frame: two months afer the end of radiotherapy
Gastrointestinal toxicity after the end of radiotherapy were reported according to CTCAE v4.0 scale
Time frame: two months afer the end of radiotherapy
Genitourinary toxicity after the end of radiotherapy were reported according to CTCAE v4.0 scale.
Time frame: two months afer the end of radiotherapy
number of patients with colostomy
Contact information is provided by the study sponsor or research team.
Joan Lozano, MD
CONTACT
Joan Lozano, MD
CONTACT
Consorci Sanitari de Terrassa
Other
Palliative Hypofractionated Radiotherapy in Non-operable Rectal Cancer: A Retrospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04098471
Colorectal Neoplasms, Digestive System Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07104604
Colorectal Neoplasms, Digestive System Diseases
Shantou, Guangdong, China
View Trial DetailsNCT06340646
Adenocarcinoma, Blood Protein Disorders
St Louis, Missouri, United States
View Trial DetailsNCT06205485
Colorectal Neoplasms, Digestive System Diseases
Phoenix, Arizona, United States
View Trial Details